Atea Pharmaceuticals (AVIR) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed ARS Pharmaceuticals (SPRY) over the past year, gaining 33.3% versus a loss of 61.0%. Over five years, AVIR leads with a -51.4% price change compared with -58.8% for SPRY. Atea Pharmaceuticals is the larger company by market cap ($318.0 million vs $297.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | SPRY |
|---|---|---|
| Share price | $3.96 | $2.96 |
| Market cap | $318.00M | $297.56M |
| 1-day change | +0.76% | -11.90% |
| YTD return | +10.92% | -74.59% |
| 1-year return | +33.33% | -61.00% |
| 5-year return | -51.35% | -58.83% |
| EPS (TTM) | $-1.95 | $-2.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $84.28M |
| Revenue growth (YoY) | — | -5.46% |
| Net income (latest FY) | $-158.35M | $-171.30M |
| Operating margin | — | -212.92% |
| Net margin | — | -203.25% |
| 52-week high | $6.45 | $13.15 |
| 52-week low | $2.96 | $2.44 |
| Distance from 52-week high | -38.60% | -77.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +127.27% | +474.32% |
| Average volume | 290.60K | 1.83M |
| Shares outstanding | 80.30M | 100.53M |
| Employees | 55 | 203 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed SPRY by 94.3 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Health Care · Biotechnology: Pharmaceutical Preparations · 203 employees
AVIR vs SPRY FAQ
Which is bigger, Atea Pharmaceuticals or ARS Pharmaceuticals?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $318.00M compared with $297.56M for ARS Pharmaceuticals (SPRY).
Which stock has performed better over the past year, AVIR or SPRY?
AVIR returned +33.33% over the past 12 months, compared with -61.00% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.